Stryker Corporation (SYK) 10-Year Financial Performance & Capital Metrics

SYK • • Industrial / General

HealthcareMedical DevicesOrthopedic & Musculoskeletal DevicesJoint Reconstruction & Orthopedic Implants

AboutStryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.Show more

Revenue $22.59B +10.2%
EBITDA $6.11B +15.1%
Net Income $2.99B -5.4%
EPS (Diluted) 7.76 -5.9%
Gross Margin 61.87% +1.5%
EBITDA Margin 27.05% +4.4%
Operating Margin 22.4% +7.2%
Net Margin 13.25% -14.2%
ROE 15.26% -15.1%
ROIC 12.61% +12.7%
Debt/Equity 0.68 -5.7%
Interest Coverage 12.78 +6.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Dividend Aristocrat: 33 years of consecutive increases
✓Strong Piotroski F-Score: 7/9
✓FCF machine: 15.4% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Good 3Y average ROE of 16.1%
✓Healthy 5Y average net margin of 12.9%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y8.85%

5Y8.71%

3Y9.72%

TTM10.95%

Profit (Net Income) CAGR

10Y19.24%

5Y7.52%

3Y14.5%

TTM-18.02%

EPS CAGR

10Y19.2%

5Y7.21%

3Y14.13%

TTM-18.44%

ROCE

10Y Avg14.22%

5Y Avg12.94%

3Y Avg13.67%

Latest15.03%

Peer Comparison

Joint Reconstruction & Orthopedic Implants

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SYKStryker Corporation	136.07B	355.82	45.85	10.23%	12.07%	13.51%	2.56%	0.68
SNNSmith & Nephew plc	13.54B	31.90	33.94	4.7%	6.88%	14.44%	4.48%	0.63
ZBHZimmer Biomet Holdings, Inc.	17.51B	88.34	19.94	3.85%	10.05%	6.31%	6.53%	0.50
CNMDCONMED Corporation	1.24B	40.03	9.40	5%	4.75%	6.35%	12.41%	0.94
DHAIDIH Holding US, Inc.	6.7K	0.00	-0.00	-2.5%	-13.8%
LFWDLifeward Ltd.	12.57M	0.69	-0.21	85.24%	-121.82%	-233.98%		0.05
ANIKAnika Therapeutics, Inc.	137.72M	9.55	-2.49	-0.73%	-40.83%	-22.5%		0.17
SNWVSANUWAVE Health, Inc.	245.02M	28.57	-4.06	59.99%	-17.06%		0.8%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	9.95B	11.32B	12.44B	13.6B	14.88B	14.35B	17.11B	18.45B	20.5B	22.59B
Revenue Growth %	0.03%	0.14%	0.1%	0.09%	0.09%	-0.04%	0.19%	0.08%	0.11%	0.1%
Cost of Goods Sold+	3.56B	4.08B	4.54B	5B	5.5B	5.6B	6.4B	7.41B	8B	8.62B
COGS % of Revenue	0.36%	0.36%	0.36%	0.37%	0.37%	0.39%	0.37%	0.4%	0.39%	0.38%
Gross Profit+	6.39B	7.25B	7.9B	8.6B	9.38B	8.75B	10.71B	11.04B	12.49B	13.98B
Gross Margin %	0.64%	0.64%	0.64%	0.63%	0.63%	0.61%	0.63%	0.6%	0.61%	0.62%
Gross Profit Growth %	0.03%	0.13%	0.09%	0.09%	0.09%	-0.07%	0.22%	0.03%	0.13%	0.12%
Operating Expenses+	4.13B	4.67B	5.14B	5.5B	5.99B	5.72B	6.95B	7.31B	8.21B	8.92B
OpEx % of Revenue	0.42%	0.41%	0.41%	0.4%	0.4%	0.4%	0.41%	0.4%	0.4%	0.39%
Selling, General & Admin	3.51B	3.95B	4.35B	4.63B	5.02B	4.82B	5.81B	6.08B	6.92B	7.5B
SG&A % of Revenue	0.35%	0.35%	0.35%	0.34%	0.34%	0.34%	0.34%	0.33%	0.34%	0.33%
Research & Development	625M	715M	787M	862M	971M	905M	1.13B	1.23B	1.29B	1.41B
R&D % of Revenue	0.06%	0.06%	0.06%	0.06%	0.07%	0.06%	0.07%	0.07%	0.06%	0.06%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	2.25B	2.58B	2.77B	3.1B	3.39B	3.03B	3.76B	3.73B	4.28B	5.06B
Operating Margin %	0.23%	0.23%	0.22%	0.23%	0.23%	0.21%	0.22%	0.2%	0.21%	0.22%
Operating Income Growth %	0.01%	0.14%	0.07%	0.12%	0.09%	-0.11%	0.24%	-0.01%	0.15%	0.18%
EBITDA+	2.65B	3.12B	3.41B	3.83B	4.17B	3.84B	4.75B	4.73B	5.31B	6.11B
EBITDA Margin %	0.27%	0.28%	0.27%	0.28%	0.28%	0.27%	0.28%	0.26%	0.26%	0.27%
EBITDA Growth %	0.02%	0.18%	0.09%	0.12%	0.09%	-0.08%	0.24%	-0%	0.12%	0.15%
D&A (Non-Cash Add-back)	397M	546M	642M	723M	778M	812M	990M	998M	1.03B	1.05B
EBIT	1.84B	2.15B	2.31B	2.62B	2.85B	2.27B	2.62B	3.02B	4.03B	3.89B
Net Interest Income+	-94M	-199M	-187M	-145M	-132M	-213M	-269M	-243M	-281M	-257M
Interest Income	14M	29M	60M	119M	155M	102M	68M	94M	75M	139M
Interest Expense	108M	228M	247M	264M	287M	315M	337M	337M	356M	396M
Other Income/Expense	-517M	-656M	-704M	-748M	-826M	-1.07B	-1.48B	-1.05B	-608M	-1.57B
Pretax Income+	1.74B	1.92B	2.06B	2.36B	2.56B	1.95B	2.28B	2.68B	3.67B	3.49B
Pretax Margin %	0.17%	0.17%	0.17%	0.17%	0.17%	0.14%	0.13%	0.15%	0.18%	0.15%
Income Tax+	296M	274M	1.04B	-1.2B	479M	355M	287M	325M	508M	499M
Effective Tax Rate %	0.83%	0.86%	0.49%	1.51%	0.81%	0.82%	0.87%	0.88%	0.86%	0.86%
Net Income+	1.44B	1.65B	1.02B	3.55B	2.08B	1.6B	1.99B	2.36B	3.17B	2.99B
Net Margin %	0.14%	0.15%	0.08%	0.26%	0.14%	0.11%	0.12%	0.13%	0.15%	0.13%
Net Income Growth %	1.79%	0.14%	-0.38%	2.48%	-0.41%	-0.23%	0.25%	0.18%	0.34%	-0.05%
Net Income (Continuing)	1.44B	1.65B	1.02B	3.55B	2.08B	1.6B	1.99B	2.36B	3.17B	2.99B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	14M	0	0	0	0	0	0	0
EPS (Diluted)+	3.78	4.35	2.68	9.34	5.48	4.20	5.22	6.17	8.25	7.76
EPS Growth %	1.82%	0.15%	-0.38%	2.49%	-0.41%	-0.23%	0.24%	0.18%	0.34%	-0.06%
EPS (Basic)	3.82	4.40	2.73	9.50	5.57	4.26	5.29	6.23	8.34	7.86
Diluted Shares Outstanding	380.9M	378.5M	380.1M	380.3M	379.9M	380.3M	382.3M	382.2M	383.7M	385.6M
Basic Shares Outstanding	376.6M	374.1M	374M	374.1M	374M	375.5M	377M	378.2M	379.6M	381M
Dividend Payout Ratio	0.36%	0.34%	0.62%	0.2%	0.37%	0.54%	0.48%	0.45%	0.36%	0.41%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.94B	7.86B	7.99B	9.73B	11.36B	9.71B	10.02B	10.28B	12.52B	14.85B
Cash & Short-Term Investments	4.08B	3.38B	2.79B	3.7B	4.42B	3.02B	3.02B	1.93B	3.05B	4.49B
Cash Only	3.38B	3.32B	2.54B	3.62B	4.34B	2.94B	2.94B	1.84B	2.97B	3.65B
Short-Term Investments	700M	68M	251M	83M	88M	81M	75M	84M	82M	841M
Accounts Receivable	1.66B	1.97B	2.2B	2.33B	2.89B	2.7B	3.02B	3.56B	3.77B	3.99B
Days Sales Outstanding	60.99	63.4	64.47	62.58	70.94	68.7	64.47	70.53	67.04	64.41
Inventory	1.64B	2.03B	2.46B	2.96B	3.28B	3.49B	3.31B	4B	4.84B	4.77B
Days Inventory Outstanding	168.09	181.65	198.13	215.67	217.73	227.82	189.03	196.81	220.85	202.26
Other Current Assets	0	480M	537M	747M	760M	488M	662M	787M	857M	1.59B
Total Non-Current Assets+	8.3B	12.57B	14.19B	17.5B	18.81B	24.62B	24.61B	26.61B	27.39B	28.12B
Property, Plant & Equipment	1.2B	1.57B	1.98B	2.29B	2.95B	3.17B	3.25B	3.44B	3.71B	3.96B
Fixed Asset Turnover	8.30x	7.22x	6.30x	5.94x	5.04x	4.52x	5.26x	5.36x	5.53x	5.70x
Goodwill	4.14B	6.36B	7.17B	8.56B	9.07B	12.78B	12.92B	14.88B	15.24B	15.86B
Intangible Assets	1.79B	3.51B	3.48B	4.16B	4.23B	5.55B	4.84B	4.88B	4.59B	4.39B
Long-Term Investments	0	0	0	0	0	4M	66M	90M	2M	39M
Other Non-Current Assets	674M	839M	1.3B	801M	985M	1.58B	1.78B	1.9B	2.18B	2.13B
Total Assets+	16.25B	20.43B	22.18B	27.23B	30.17B	34.33B	34.63B	36.88B	39.91B	42.97B
Asset Turnover	0.61x	0.55x	0.56x	0.50x	0.49x	0.42x	0.49x	0.50x	0.51x	0.53x
Asset Growth %	-0.08%	0.26%	0.09%	0.23%	0.11%	0.14%	0.01%	0.07%	0.08%	0.08%
Total Current Liabilities+	2.81B	2.55B	3.29B	4.81B	4.4B	5.04B	4.55B	6.3B	7.92B	7.62B
Accounts Payable	410M	437M	487M	646M	675M	810M	1.13B	1.41B	1.52B	1.68B
Days Payables Outstanding	42.05	39.1	39.14	47.15	44.78	52.81	64.4	69.61	69.18	71.14
Short-Term Debt	768M	228M	632M	1.37B	945M	870M	119M	1.31B	2.24B	1.55B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.55B	1.68B	1.39B	1.71B	1.65B	2.23B	2.02B	2.14B	2.3B	2.44B
Current Ratio	2.83x	3.08x	2.43x	2.02x	2.58x	1.93x	2.20x	1.63x	1.58x	1.95x
Quick Ratio	2.24x	2.28x	1.68x	1.41x	1.84x	1.23x	1.47x	1.00x	0.97x	1.32x
Cash Conversion Cycle	187.03	205.94	223.46	231.11	243.89	243.7	189.11	197.73	218.71	195.53
Total Non-Current Liabilities+	4.21B	7.74B	8.73B	10.69B	12.96B	16.2B	15.21B	13.96B	13.4B	14.72B
Long-Term Debt	3.23B	6.69B	6.59B	8.49B	10.23B	13.23B	12.47B	11.86B	10.9B	12.19B
Capital Lease Obligations	0	0	0	0	301M	325M	310M	357M	356M	379M
Deferred Tax Liabilities	35M	55M	47M	54M	108M	117M	68M	67M	63M	82M
Other Non-Current Liabilities	945M	996M	2.1B	2.15B	2.32B	2.53B	2.35B	1.68B	2.08B	2.07B
Total Liabilities	7.71B	10.88B	12.22B	15.5B	17.36B	21.25B	19.75B	20.27B	21.32B	22.34B
Total Debt+	4B	6.91B	7.22B	9.86B	11.48B	14.43B	12.9B	13.53B	13.49B	14.12B
Net Debt	619M	3.6B	4.68B	6.24B	7.14B	11.48B	9.96B	11.68B	10.52B	10.47B
Debt / Equity	0.47x	0.72x	0.72x	0.84x	0.90x	1.10x	0.87x	0.81x	0.73x	0.68x
Debt / EBITDA	1.51x	2.21x	2.12x	2.58x	2.75x	3.76x	2.71x	2.86x	2.54x	2.31x
Net Debt / EBITDA	0.23x	1.15x	1.37x	1.63x	1.71x	2.99x	2.09x	2.47x	1.98x	1.71x
Interest Coverage	20.85x	11.30x	11.20x	11.76x	11.80x	9.61x	11.17x	11.08x	12.03x	12.78x
Total Equity+	8.51B	9.55B	9.98B	11.73B	12.81B	13.08B	14.88B	16.62B	18.59B	20.63B
Equity Growth %	-0.01%	0.12%	0.05%	0.18%	0.09%	0.02%	0.14%	0.12%	0.12%	0.11%
Book Value per Share	22.34	25.23	26.26	30.84	33.71	34.40	38.91	43.47	48.46	53.51
Total Shareholders' Equity	8.51B	9.55B	9.97B	11.73B	12.81B	13.08B	14.88B	16.62B	18.59B	20.63B
Common Stock	37M	37M	37M	37M	37M	38M	38M	38M	38M	38M
Retained Earnings	7.79B	8.84B	8.99B	10.77B	11.75B	12.46B	13.48B	14.77B	16.77B	18.53B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-639M	-761M	-553M	-631M	-606M	-1.16B	-531M	-221M	-416M	-293M
Minority Interest	0	0	14M	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	899M	1.92B	1.56B	2.61B	2.19B	3.28B	3.26B	2.62B	3.71B	4.24B
Operating CF Margin %	0.09%	0.17%	0.13%	0.19%	0.15%	0.23%	0.19%	0.14%	0.18%	0.19%
Operating CF Growth %	-0.5%	1.13%	-0.19%	0.67%	-0.16%	0.5%	-0%	-0.2%	0.41%	0.14%
Net Income	1.44B	1.65B	1.02B	3.55B	2.08B	1.6B	1.99B	2.36B	3.17B	2.99B
Depreciation & Amortization	397M	546M	642M	723M	778M	812M	990M	998M	1.03B	1.05B
Stock-Based Compensation	86M	97M	113M	119M	127M	142M	171M	168M	205M	229M
Deferred Taxes	87M	-46M	36M	-1.58B	126M	48M	-237M	58M	-206M	-370M
Other Non-Cash Items	-173M	52M	-149M	1.46B	-253M	-190M	66M	-226M	19M	1.02B
Working Capital Changes	-937M	-381M	-103M	-1.67B	-670M	866M	279M	-732M	-500M	-683M
Change in Receivables	-151M	-192M	-162M	-60M	-563M	354M	-377M	-579M	-175M	-321M
Change in Inventory	-115M	-299M	-320M	-385M	-400M	27M	-189M	-762M	-797M	-206M
Change in Payables	35M	-16M	21M	116M	63M	100M	329M	290M	77M	192M
Cash from Investing+	1.96B	-4.19B	-1.61B	-2.86B	-1.46B	-4.7B	-859M	-2.92B	-962M	-3B
Capital Expenditures	-270M	-490M	-598M	-572M	-649M	-487M	-525M	-588M	-575M	-755M
CapEx % of Revenue	0.03%	0.04%	0.05%	0.04%	0.04%	0.03%	0.03%	0.03%	0.03%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-3M	-1M	-2M	1M	1M	-1M	39M	1M	43M
Cash from Financing+	-1.14B	2.26B	-794M	1.33B	3M	-11M	-2.37B	-749M	-1.59B	-525M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-521M	-568M	-636M	-703M	-778M	-863M	-950M	-1.05B	-1.14B	-1.22B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	32M	-73M	-227M	-124M	-205M	-27M	-148M	-48M	-23M	-51M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	629M	1.43B	961M	2.04B	1.54B	2.79B	2.74B	2.04B	3.14B	3.49B
FCF Margin %	0.06%	0.13%	0.08%	0.15%	0.1%	0.19%	0.16%	0.11%	0.15%	0.15%
FCF Growth %	-0.59%	1.27%	-0.33%	1.12%	-0.24%	0.81%	-0.02%	-0.26%	0.54%	0.11%
FCF per Share	1.65	3.76	2.53	5.36	4.06	7.34	7.16	5.33	8.17	9.04
FCF Conversion (FCF/Net Income)	0.62x	1.16x	1.53x	0.73x	1.05x	2.05x	1.64x	1.11x	1.17x	1.42x
Interest Paid	101M	180M	231M	248M	286M	304M	325M	324M	356M	396M
Taxes Paid	497M	510M	312M	539M	457M	323M	622M	505M	693M	989M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	16.82%	18.24%	10.45%	32.73%	16.98%	12.35%	14.26%	14.97%	17.98%	15.26%
Return on Invested Capital (ROIC)	16.97%	17.35%	14.93%	14.27%	13.4%	10.2%	11.43%	10.54%	11.18%	12.61%
Gross Margin	64.22%	63.98%	63.51%	63.23%	63.03%	60.99%	62.6%	59.84%	60.95%	61.87%
Net Margin	14.47%	14.54%	8.2%	26.12%	13.99%	11.14%	11.66%	12.78%	15.44%	13.25%
Debt / Equity	0.47x	0.72x	0.72x	0.84x	0.90x	1.10x	0.87x	0.81x	0.73x	0.68x
Interest Coverage	20.85x	11.30x	11.20x	11.76x	11.80x	9.61x	11.17x	11.08x	12.03x	12.78x
FCF Conversion	0.62x	1.16x	1.53x	0.73x	1.05x	2.05x	1.64x	1.11x	1.17x	1.42x
Revenue Growth	2.8%	13.86%	9.88%	9.3%	9.43%	-3.58%	19.21%	7.84%	11.11%	10.23%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
MedSurg	3.9B	4.89B	5.56B	6.04B	6.57B	6.4B	9.54B	10.61B	11.84B	13.52B
MedSurg Growth	-	25.65%	13.55%	8.78%	8.75%	-2.65%	49.03%	11.25%	11.54%	14.21%
Orthopaedics	4.22B	4.42B	4.71B	4.99B	5.25B	4.96B	-	-	-	9.08B
Orthopaedics Growth	-	4.71%	6.58%	5.90%	5.23%	-5.58%	-	-	-	-
Orthopaedics and Spine	1.83B	2.01B	-	2.56B	3.06B	2.99B	7.57B	7.84B	8.66B	-
Orthopaedics and Spine Growth	-	9.90%	-	-	19.22%	-2.16%	153.01%	3.54%	10.51%	-
Neurotechnology & Spine	-	-	2.17B	-	-	-	-	-	-	-
Neurotechnology & Spine Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
United States	-	-	9.06B	-	10.96B	10.46B	12.32B	13.64B	15.26B	16.94B
United States Growth	-	-	-	-	-	-4.58%	17.85%	10.69%	11.87%	11.05%
EMEA	1.27B	1.44B	-	1.79B	1.89B	1.82B	2.3B	2.35B	2.62B	2.9B
EMEA Growth	-	13.81%	-	-	5.30%	-3.71%	26.46%	2.13%	11.50%	10.66%
Asia Pacific	1.25B	1.31B	1.41B	1.53B	1.62B	1.63B	1.97B	1.89B	1.95B	2.02B
Asia Pacific Growth	-	5.04%	7.53%	8.42%	5.55%	0.80%	21.04%	-4.46%	3.24%	3.80%
Other foreign countries	312M	322M	-	428M	422M	448M	515M	578M	677M	735M
Other foreign countries Growth	-	3.21%	-	-	-1.40%	6.16%	14.96%	12.23%	17.13%	8.57%
Europe, Middle East, Africa	-	-	1.57B	-	-	-	-	-	-	-
Europe, Middle East, Africa Growth	-	-	-	-	-	-	-	-	-	-
Other Countries	-	-	405M	-	-	-	-	-	-	-
Other Countries Growth	-	-	-	-	-	-	-	-	-	-
UNITED STATES	7.12B	8.25B	-	-	-	-	-	-	-	-
UNITED STATES Growth	-	15.89%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Stryker Corporation (SYK) has a price-to-earnings (P/E) ratio of 45.9x. This suggests investors expect higher future growth.

Growth & Financials

Stryker Corporation (SYK) reported $24.38B in revenue for fiscal year 2024. This represents a 193% increase from $8.31B in 2011.

Stryker Corporation (SYK) grew revenue by 10.2% over the past year. This is steady growth.

Yes, Stryker Corporation (SYK) is profitable, generating $2.94B in net income for fiscal year 2024 (13.2% net margin).

Dividend & Returns

Yes, Stryker Corporation (SYK) pays a dividend with a yield of 0.89%. This makes it attractive for income-focused investors.

Stryker Corporation (SYK) has a return on equity (ROE) of 15.3%. This is reasonable for most industries.

Stryker Corporation (SYK) generated $4.07B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...